Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pyronaridine Tetraphosphate,Artesunate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Medicines for Malaria Venture
Deal Size : $0.2 million
Deal Type : Funding
Mangalam Drugs & Organics Awarded US$ 274,800 Grant by MMV
Details : The grant will support research and development efforts aimed at improving the technology and efficiency of pyronaridine production for pyronaridine-artesunate combination therapy, Pyramax.
Brand Name : Pyramax
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 27, 2024
Lead Product(s) : Pyronaridine Tetraphosphate,Artesunate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Medicines for Malaria Venture
Deal Size : $0.2 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?
Reset All
